adamantane has been researched along with Apoplexy in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergmark, BA; Bhatt, DL; Bohula, E; Braunwald, E; Cahn, A; Gurmu, Y; Morrow, DA; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG | 1 |
| Chuang, TY; Huang, HX; Hung, YW; Lan, MY; Lin, YY; Tsai, CH; Yeh, CF | 1 |
| Hardy, G | 1 |
| Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA | 1 |
| Dangi-Garimella, S | 1 |
| Bhatt, DL; Bonnici, F; Braunwald, E; Cahn, A; Frederich, R; Hirshberg, B; Kumar, KM; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Smahelova, A; Stahre, C; Teoh, H | 1 |
| Bhatt, DL; Braunwald, E; Cahn, A; Cavender, MA; Davidson, J; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG | 1 |
| Carroll, MA; Chander, PN; Falck, JR; Li, J; Sangras, B; Stier, CT | 1 |
| Alexander, JH; Berglind, N; Chen, R; Donovan, M; Fiedorek, FT; Frederich, R; Harris, S; Mahaffey, KW; Wolf, R | 1 |
| Alkayed, NJ; Falck, JR; Grafe, M; Hammock, BD; Koerner, IP; Luria, A; Morisseau, C; Noppens, R; Tsai, HJ; Zhang, W | 1 |
5 trial(s) available for adamantane and Apoplexy
| Article | Year |
|---|---|
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.
Topics: Adamantane; Aged; Body Mass Index; Calibration; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endpoint Determination; Female; Humans; Life Style; Male; Middle Aged; Myocardial Infarction; Registries; Risk Assessment; Risk Factors; Secondary Prevention; Stroke | 2018 |
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome | 2015 |
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Risk; Stroke | 2016 |
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Risk; Stroke | 2010 |
5 other study(ies) available for adamantane and Apoplexy
| Article | Year |
|---|---|
Inhibition of soluble epoxide hydrolase regulates monocyte/macrophage polarization and improves neurological outcome in a rat model of ischemic stroke.
Topics: Adamantane; Animals; Brain Ischemia; Cell Polarity; Disease Models, Animal; Encephalitis; Epoxide Hydrolases; Lauric Acids; Macrophages; Male; Monocytes; Rats, Inbred WKY; Rotarod Performance Test; Stroke | 2019 |
Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Humans; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2013 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.
Topics: Adamantane; Animals; Eicosanoic Acids; Enzyme Inhibitors; Epithelial Sodium Channels; Epoxide Hydrolases; Hypertension; Lauric Acids; Male; Rats; Rats, Inbred SHR; Sodium Chloride; Stroke | 2008 |
Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Topics: Adamantane; Animals; Antipyrine; Autoradiography; Blood-Brain Barrier; Blotting, Western; Capillaries; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Epoxide Hydrolases; Immunohistochemistry; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Middle Cerebral Artery; Nerve Tissue Proteins; Stroke; Urea | 2007 |